High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective

Journal of Hepatology

Volumn 48, Issue 5, 2008, Pages 792-800

  Cullen, Susan N ^a   Rust, Christian ^b   Fleming, Kenneth ^c   Edwards, Cathryn ^d   Beuers, Ulrich ^b,e   Chapman, Roger W ^c  

^a WYCOMBE HOSPITAL   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d TORBAY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Mayo risk score; Primary sclerosing cholangitis; Survival probability; Ursodeoxycholic acid

Indexed keywords

AZATHIOPRINE; BILE ACID; MERCAPTOPURINE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE ACID BLOOD LEVEL; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTIOUS DIARRHEA; LIBIDO DISORDER; LIVER BIOPSY; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; PATIENT ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; CHOLANGITIS, SCLEROSING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; URSODEOXYCHOLIC ACID;

EID: 40949086356     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.12.023     Document Type: Article

References (20)

1. Aadland E., Schrumpf E., Fausa O., Elgjo K., Heilo A., Aakhus T., et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 22 (1987) 655-664
2. Paumgartner G., and Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36 (2002) 525-531
3. Paumgartner G., and Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 8 (2004) 67-81
4. Jazrawi R.P., de Caestecker J.S., Goggin P.M., Britten A.J., Joseph A.E., Maxwell J.D., et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 106 (1994) 134-142
5. Sola S., Amaral J.D., Castro R.E., Ramalho R.M., Borralho P.M., Kren B.T., et al. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 42 (2005) 925-934
6. Qiao L., Yacoub A., Studer E., Gupta S., Pei X.Y., Grant S., et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 35 (2002) 779-789
7. Schoemaker M.H., Conde de la Rosa L., Buist-Homan M., Vrenken T.E., Havinga R., Poelstra K., et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39 (2004) 1563-1573
8. Hayashi H., Higuchi T., Ichimiya H., Hishida N., and Sakamoto N. Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid. Gastroenterology 99 (1990) 533-535
9. Chazouilleres O., Poupon R., Capron J.P., Metman E.H., Dhumeaux D., Amouretti M., et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 11 (1990) 120-123
10. Beuers U., Spengler U., Kruis W., Aydemir U., Wiebecke B., Heldwein W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16 (1992) 707-714
11. Stiehl A., Walker S., Stiehl L., Rudolph G., Hofmann W.J., and Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 20 (1994) 57-64
12. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336 (1997) 691-695
13. Rost D., Rudolph G., Kloeters-Plachky P., and Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40 (2004) 693-698
14. Mitchell S.A., Bansi D.S., Hunt N., Von Bergmann K., Fleming K.A., and Chapman R.W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121 (2001) 900-907
15. Harnois D.M., Angulo P., Jorgensen R.A., Larusso N.F., and Lindor K.D. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96 (2001) 1558-1562
16. Olsson R., Boberg K.M., de Muckadell O.S., Lindgren S., Hultcrantz R., Folvik G., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129 (2005) 1464-1472
17. Ludwig J., Barham S.S., LaRusso N.F., Elveback L.R., Wiesner R.H., and McCall J.T. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1 (1981) 632-640
18. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
19. Kim W.R., Therneau T.M., Wiesner R.H., Poterucha J.J., Benson J.T., Malinchoc M., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75 (2000) 688-694
20. Kim W.R., Poterucha J.J., Wiesner R.H., LaRusso N.F., Lindor K.D., Petz J., et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 29 (1999) 1643-1648